Confocal Laser Endomicroscopy (CLE) in Patients With Diarrhea

This study is currently recruiting participants.
Verified January 2013 by University of Erlangen-Nürnberg Medical School
Sponsor:
Information provided by (Responsible Party):
Helmut Neumann, University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier:
NCT01072110
First received: February 17, 2010
Last updated: January 23, 2013
Last verified: January 2013

February 17, 2010
January 23, 2013
February 2010
January 2014   (final data collection date for primary outcome measure)
To determine the frequency of different gastrointestinal disorders as the cause of diarrhea in patients at a tertiary referral center using confocal laser endomicroscopy. [ Time Frame: February 2012 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01072110 on ClinicalTrials.gov Archive Site
To investigate whether CLE has a higher sensitivity and specificity than standard colonoscopy in the diagnosis of the cause of diarrhea. [ Time Frame: February 2012 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Confocal Laser Endomicroscopy (CLE) in Patients With Diarrhea
Confocal Laser Endomicroscopy in Patients With Diarrhea

The main objective of this study is to determine the frequency of different gastrointestinal disorders as the cause of diarrhea in patients at a tertiary referral center using confocal laser endomicroscopy.

Background:

Diarrhea is characterized by frequent, loose, and watery bowel movements. Common causes include various gastrointestinal infections (e.g. clostridium difficile, salmonella), inflammatory bowel disease (ulcerative colitis, Crohn´s disease), drugs (e.g. antibiotics) and malabsorption syndromes (e.g. celiac and Whipple's disease). Confocal laser endomicroscopy (CLE) is rapidly emerging as a valuable tool for gastrointestinal endoscopic imaging, enabling the endoscopist to obtain an "optical biopsy" of the gastrointestinal mucosa during the endoscopic procedure.

Scope:

In patients with diarrhea.

Methods:

Patients were randomized in two groups. Group 1: Patients underwent standard video colonoscopy for the evaluation of their symptoms. Group 2: During the endoscopic procedure CLE will be performed additionally.

Procedure:

The patient underwent colonoscopy. In Group 2 patients´ will receive intravenous fluorescein or topical mucosal staining with acriflavin or cresyl violet during the procedure, followed by in-vivo CLE of the tissue. Confocal images are digitally saved and analyzed afterwards.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients of a tertiary referral hospital.

Diarrhea
  • Procedure: Colonoscopy
    Patients will undergo colonoscopy for evaluation of their symptoms.
  • Procedure: Confocal Laser Endomicroscopy
    Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
  • Group 1: Patients with diarrhea undergoing endoscopy
    Standard video colonoscope.
    Intervention: Procedure: Colonoscopy
  • Group 2: Patients with diarrhea undergoing endoscopy.
    Confocal laser endomicroscopy (CLE).
    Intervention: Procedure: Confocal Laser Endomicroscopy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
February 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent
  • Age 18-85 years
  • Ability of subjects to understand character and individual consequences of clinical trial
  • Subjects undergoing colonoscopy

Exclusion Criteria:

  • Inability to provide written informed consent
  • Severe Coagulopathy (Prothrombin time < 50% of control, Partial thromboplastin time > 50 s)
  • Impaired renal function (Creatinine > 1.2 mg/dl)
  • Pregnancy or breast feeding
  • Active gastrointestinal bleeding
  • Known allergy to fluorescein, acriflavin or cresyl violet
  • Residing in institutions (e.g. prison)
Both
18 Years to 85 Years
No
Contact: Markus F Neurath, M.D, Ph.D. markus.neurath@uk-erlangen.de
Contact: Helmut Neumann, M.D., Ph.D. helmut.neumann@uk-erlangen.de
Germany
 
NCT01072110
HN-0001
No
Helmut Neumann, University of Erlangen-Nürnberg Medical School
University of Erlangen-Nürnberg Medical School
Not Provided
Principal Investigator: Markus F. Neurath, M.D., Ph.D. Department of Medicine I, University of Erlangen-Nuremberg
University of Erlangen-Nürnberg Medical School
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP